Advanced Pharmacology Prac ce Quiz
Module 1: Founda onal Principles & General Pharmacology
Level: MSN / Nurse Prac oner
Format: 50 original case-based mul ple-choice ques ons
Focus: Pharmacokine cs, pharmacodynamics, therapeu c index, half-life/steady state,
medica on safety, and prescrip on requirements.
Ques ons 1–10: Pharmacokine cs — Absorp on, Distribu on, Metabolism, and Excre on
Ques on 1 — Gastric pH and Drug Absorp on
A 68-year-old pa ent with gastroesophageal reflux disease takes an oral weakly acidic
medica on that requires an acidic gastric environment for op mal dissolu on. The pa ent
recently began taking a proton-pump inhibitor. Two weeks later, the medica on's clinical effect
has decreased despite adherence to the prescribed dose.
Which pharmacokine c altera on best explains this finding?
A. Increased renal clearance caused by enhanced glomerular filtra on
B. Reduced gastrointes nal absorp on caused by increased gastric pH
C. Increased hepa c metabolism caused by CYP450 induc on
D. Increased protein binding caused by decreased gastric acidity
Correct Answer: B
Clinical Ra onale
B is correct. Increasing gastric pH can alter the dissolu on and ioniza on characteris cs of some
orally administered medica ons. A weakly acidic drug may become less efficiently absorbed
when gastric acidity is substan ally reduced, poten ally decreasing systemic bioavailability and
therapeu c exposure.
, A is incorrect: Renal clearance would influence elimina on a er systemic absorp on
and would not explain impaired ini al gastrointes nal uptake.
C is incorrect: CYP450 induc on is a metabolic phenomenon occurring primarily a er
absorp on; it is not the direct consequence of gastric alkaliniza on.
D is incorrect: Plasma protein binding occurs primarily a er systemic absorp on and is
not meaningfully explained by increased gastric pH.
Clinical pearl: When an oral medica on unexpectedly loses efficacy a er ini a on of acid-
suppressive therapy, evaluate whether altered gastric pH can affect its bioavailability.
Ques on 2 — First-Pass Metabolism
A pa ent receives the same medica on by oral and intravenous routes. The intravenous dose
produces substan ally greater systemic exposure than an equivalent oral dose.
Which mechanism most directly accounts for this difference?
A. Increased renal tubular secre on a er intravenous administra on
B. Greater plasma protein binding following oral administra on
C. Presystemic intes nal and hepa c metabolism following oral administra on
D. Delayed distribu on into peripheral ssues following intravenous administra on
Correct Answer: C
Clinical Ra onale
C is correct. Oral medica ons pass through the gastrointes nal tract and portal circula on
before reaching systemic circula on. Metabolism within the intes nal wall and liver can
substan ally reduce the frac on of drug reaching systemic circula on. This is known as first-
pass or presystemic metabolism.
A is incorrect: Renal secre on occurs a er the drug enters systemic circula on and does
not explain reduced oral bioavailability.
, B is incorrect: Protein binding can affect distribu on and free-drug concentra on but is
not the principal explana on for first-pass loss.
D is incorrect: Distribu on occurs a er systemic drug entry and does not account for
reduced oral bioavailability.
Ques on 3 — Protein Binding
A pa ent with severe hypoalbuminemia is prescribed a medica on that is normally 98%
albumin-bound. Shortly a er therapy begins, the pa ent develops dizziness and excessive
seda on despite receiving the usual dose.
Which pharmacokine c change is most likely responsible?
A. Increased concentra on of unbound, pharmacologically ac ve drug
B. Decreased hepa c extrac on caused by increased albumin availability
C. Increased gastrointes nal absorp on caused by reduced protein binding
D. Decreased volume of distribu on because less drug enters ssues
Correct Answer: A
Clinical Ra onale
A is correct. Albumin binds many acidic and neutral medica ons. When albumin concentra on
decreases, fewer binding sites are available, poten ally increasing the free frac on of highly
protein-bound drugs. Because the unbound frac on is generally pharmacologically ac ve and
available for distribu on and elimina on, toxicity may occur even when the total measured
concentra on appears acceptable.
B is incorrect: Hypoalbuminemia does not increase albumin availability.
C is incorrect: Plasma protein binding occurs a er absorp on and does not directly
increase gastrointes nal absorp on.
, D is incorrect: Reduced protein binding can actually increase ssue distribu on for some
medica ons and therefore may increase, rather than decrease, volume of distribu on.
Ques on 4 — Volume of Distribu on
A highly lipophilic medica on rapidly leaves the bloodstream and accumulates extensively in
adipose ssue. Which pharmacokine c characteris c would most likely be observed?
A. Low volume of distribu on
B. High volume of distribu on
C. Complete absence of ssue distribu on
D. Reduced drug sequestra on in peripheral ssues
Correct Answer: B
Clinical Ra onale
B is correct. A drug that extensively distributes from plasma into ssues can have a large
apparent volume of distribu on (Vd). Lipophilic drugs commonly par on into adipose and
other ssues, resul ng in rela vely li le drug remaining within the vascular compartment.
A is incorrect: A low Vd indicates that a rela vely large propor on of the drug remains
within plasma or extracellular fluid.
C is incorrect: The scenario explicitly describes extensive ssue distribu on.
D is incorrect: Tissue sequestra on is increased, not reduced.
Clinical implica on: Drugs with very large Vd values may have prolonged elimina on because
substan al amounts of drug remain stored outside the circula on.
Ques on 5 — CYP450 Inhibi on
Module 1: Founda onal Principles & General Pharmacology
Level: MSN / Nurse Prac oner
Format: 50 original case-based mul ple-choice ques ons
Focus: Pharmacokine cs, pharmacodynamics, therapeu c index, half-life/steady state,
medica on safety, and prescrip on requirements.
Ques ons 1–10: Pharmacokine cs — Absorp on, Distribu on, Metabolism, and Excre on
Ques on 1 — Gastric pH and Drug Absorp on
A 68-year-old pa ent with gastroesophageal reflux disease takes an oral weakly acidic
medica on that requires an acidic gastric environment for op mal dissolu on. The pa ent
recently began taking a proton-pump inhibitor. Two weeks later, the medica on's clinical effect
has decreased despite adherence to the prescribed dose.
Which pharmacokine c altera on best explains this finding?
A. Increased renal clearance caused by enhanced glomerular filtra on
B. Reduced gastrointes nal absorp on caused by increased gastric pH
C. Increased hepa c metabolism caused by CYP450 induc on
D. Increased protein binding caused by decreased gastric acidity
Correct Answer: B
Clinical Ra onale
B is correct. Increasing gastric pH can alter the dissolu on and ioniza on characteris cs of some
orally administered medica ons. A weakly acidic drug may become less efficiently absorbed
when gastric acidity is substan ally reduced, poten ally decreasing systemic bioavailability and
therapeu c exposure.
, A is incorrect: Renal clearance would influence elimina on a er systemic absorp on
and would not explain impaired ini al gastrointes nal uptake.
C is incorrect: CYP450 induc on is a metabolic phenomenon occurring primarily a er
absorp on; it is not the direct consequence of gastric alkaliniza on.
D is incorrect: Plasma protein binding occurs primarily a er systemic absorp on and is
not meaningfully explained by increased gastric pH.
Clinical pearl: When an oral medica on unexpectedly loses efficacy a er ini a on of acid-
suppressive therapy, evaluate whether altered gastric pH can affect its bioavailability.
Ques on 2 — First-Pass Metabolism
A pa ent receives the same medica on by oral and intravenous routes. The intravenous dose
produces substan ally greater systemic exposure than an equivalent oral dose.
Which mechanism most directly accounts for this difference?
A. Increased renal tubular secre on a er intravenous administra on
B. Greater plasma protein binding following oral administra on
C. Presystemic intes nal and hepa c metabolism following oral administra on
D. Delayed distribu on into peripheral ssues following intravenous administra on
Correct Answer: C
Clinical Ra onale
C is correct. Oral medica ons pass through the gastrointes nal tract and portal circula on
before reaching systemic circula on. Metabolism within the intes nal wall and liver can
substan ally reduce the frac on of drug reaching systemic circula on. This is known as first-
pass or presystemic metabolism.
A is incorrect: Renal secre on occurs a er the drug enters systemic circula on and does
not explain reduced oral bioavailability.
, B is incorrect: Protein binding can affect distribu on and free-drug concentra on but is
not the principal explana on for first-pass loss.
D is incorrect: Distribu on occurs a er systemic drug entry and does not account for
reduced oral bioavailability.
Ques on 3 — Protein Binding
A pa ent with severe hypoalbuminemia is prescribed a medica on that is normally 98%
albumin-bound. Shortly a er therapy begins, the pa ent develops dizziness and excessive
seda on despite receiving the usual dose.
Which pharmacokine c change is most likely responsible?
A. Increased concentra on of unbound, pharmacologically ac ve drug
B. Decreased hepa c extrac on caused by increased albumin availability
C. Increased gastrointes nal absorp on caused by reduced protein binding
D. Decreased volume of distribu on because less drug enters ssues
Correct Answer: A
Clinical Ra onale
A is correct. Albumin binds many acidic and neutral medica ons. When albumin concentra on
decreases, fewer binding sites are available, poten ally increasing the free frac on of highly
protein-bound drugs. Because the unbound frac on is generally pharmacologically ac ve and
available for distribu on and elimina on, toxicity may occur even when the total measured
concentra on appears acceptable.
B is incorrect: Hypoalbuminemia does not increase albumin availability.
C is incorrect: Plasma protein binding occurs a er absorp on and does not directly
increase gastrointes nal absorp on.
, D is incorrect: Reduced protein binding can actually increase ssue distribu on for some
medica ons and therefore may increase, rather than decrease, volume of distribu on.
Ques on 4 — Volume of Distribu on
A highly lipophilic medica on rapidly leaves the bloodstream and accumulates extensively in
adipose ssue. Which pharmacokine c characteris c would most likely be observed?
A. Low volume of distribu on
B. High volume of distribu on
C. Complete absence of ssue distribu on
D. Reduced drug sequestra on in peripheral ssues
Correct Answer: B
Clinical Ra onale
B is correct. A drug that extensively distributes from plasma into ssues can have a large
apparent volume of distribu on (Vd). Lipophilic drugs commonly par on into adipose and
other ssues, resul ng in rela vely li le drug remaining within the vascular compartment.
A is incorrect: A low Vd indicates that a rela vely large propor on of the drug remains
within plasma or extracellular fluid.
C is incorrect: The scenario explicitly describes extensive ssue distribu on.
D is incorrect: Tissue sequestra on is increased, not reduced.
Clinical implica on: Drugs with very large Vd values may have prolonged elimina on because
substan al amounts of drug remain stored outside the circula on.
Ques on 5 — CYP450 Inhibi on
